Launched in 2018, J-Clinic is a collaboration between Massachusetts Institute of Technology and the social enterprise organization Community Jameel. The initiative, which supports research from more than 30 principal investigators, is dedicated to developing AI technologies that will transform the landscape of healthcare. Efforts are multifaceted and include areas such as diagnostics, drug discovery, and personalized treatments.
While J-Clinic is dedicated to making advancements in machine learning and the clinical sciences, its primary aim is to translate those discoveries into technology that improves lives. To that end, J-Clinic collaborates with experts from the Boston healthcare and biotech environment to implement AI tools in real clinical settings.
Since the emergence of COVID-19, researchers at J-Clinic have begun several machine-learning efforts focused on curbing the virus. One initiative is AI Cures, a collaborative project to rapidly identify antiviral molecules for SARS-CoV-2. In other spaces, J-Clinic researchers are developing improved methods of testing - including a CRISPR-based test - as well as models to track the spread of the virus. In the ongoing fight against COVID-19, J-Clinic continues to expand its connections with research institutions from around the world in order to accelerate these efforts.
Collaborating with the future-oriented RETHINK initiative at ETH Zurich enables J-Clinic to align itself with researchers who connect design thinking with artificial intelligence bridging concepts across discipline-specific boundaries. ETH Zurich – the Swiss Federal Institute of Technology in Zurich, Switzerland – and home to RETHINK, values freedom, individual responsibility, and an entrepreneurial spirit. The J-Clinic - RETHINK partnership affords a mutually beneficial relationship and access to a strong global network for scientific exchange.